Stelac Advisory Services’s Moderna MRNA Stock Holding History

Stelac Advisory Services’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-343	Closed	-$132K	–	213
2021 Q3	$132K	Sell	343 -151	-31%	-$55.7K	0.04%	200
2021 Q2	$116K	Buy	+494	New	+$88.3K	0.03%	266
2021 Q1	–	Sell	-1,007	Closed	-$105K	–	257
2020 Q4	$105K	Buy	+1,007	New	+$102K	0.03%	248

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stelac Advisory Services's MRNA Position: Q4 2021 in Review

Stelac Advisory Services sold out of Moderna (MRNA) in Q4 2021, closing a stake of 343 shares — an estimated $132K sold.

Stelac Advisory Services first reported a position in MRNA in Q4 2020 and held it in 3 quarters. The position peaked at $132K in Q3 2021. 1,109 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Stelac Advisory Services reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Stelac Advisory Services sold 343 Moderna shares in Q4 2021, an estimated $132K.
Stelac Advisory Services first reported a position in Moderna in Q4 2020 and held it in 3 quarters.
Stelac Advisory Services's Moderna position peaked at $132K in Q3 2021.
1,109 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Stelac Advisory Services's 13F filing for Q4 2021, filed 14 Feb 2022.